1
Masahiro Nomura, Yukie Takahashi, Takahiro Tanase, Hiroyuki Miyachi, Masaki Tsunoda, Tomohiro Ide, Koji Murakami: Substituted phenylpropionic acid derivatives as agonists to human peroxisome proliferator-activated receptor (PPAR) &agr;. Kyorin Pharmaceutical, Oblon Spivak McClelland Maier & Neustadt P C, January 14, 2003: US06506797 (9 worldwide citation)

The invention provides novel substituted phenylpropanoic acid derivatives that activate by binding to receptor as ligands of human peroxisome preliferant-activated receptor &agr; (PPAR&agr;), and exhibit potent decreasing action on lipids in blood (cholesterol and triglyceride).


2
Yasumichi Fukuda, Yoshikazu Asahina, Satoru Katayama, Taku Shibue, Koji Murakami, Tomohiro Ide: Bicycloamide derivative. Kyorin Pharmaceutical, Wenderoth Lind & Ponack L, July 14, 2009: US07560569 (5 worldwide citation)

Novel bicycloamide derivatives (general formula (1)) and pharmaceutically acceptable salts thereof effectively inhibit DPP-IV. The bicycloamide derivatives are represented by the general formula (1): Pharmaceutically acceptable salts thereof are also included (Example: (2S,4S)-1-[[(4-carbamoylbicycl ...


3
Yasumichi Fukuda, Yoshikazu Asahina, Kazuya Yokota, Koji Murakami, Tomohiro Ide: Bicyclo derivative. Kyorin Pharmaceutical, Wenderoth Lind & Ponack, April 7, 2009: US07514571 (5 worldwide citation)

A novel bicyclo derivative represented by the following general formula (1), or a pharmaceutically acceptable salt thereof, acts as an effective DPP-IV inhibitor: One example is (2S,4S)-1-[[N-(4-methylbicyclo[2,2,2]oct-1-yl)amino]acetyl]-4-fluoropyrrolidine-2-carbonitrile).


4
Koji Murakami, Tomohiro Ide, Toshiro Mochizuki, Takashi Kadowaki: Fatty acid CoA thioester inhibitory substance of PPAR&agr; and PPAR&ggr;. Kyorin Pharmaceutical, Oblon Spivak McClelland Maier & Neustadt P C, July 13, 2004: US06762171 (2 worldwide citation)

The invention creates a very high-novelty medicinal drug for the carbohydrate and lipid metabolism-related diseases by finding out an inhibitory substance or antagonist against PPAR &agr; and PPAR &ggr;, and relates to an application of fatty acid CoA thioester that was found out as an active inhibi ...


5
Yasumichi Fukuda, Yoshikazu Asahina, Masanori Takadoi, Kohei Ohata, Tomohiro Ide, Fumiyoshi Kobayashi, Shinji Kobayashi, Kanji Komatsu, Masanori Yamamoto: Glucokinase activator. Kyorin Pharmaceutical, Teijin Pharma, Wenderoth Lind & Ponack L, October 11, 2011: US08034819 (1 worldwide citation)

A compound, or a pharmaceutically acceptable salt thereof, represented by the formula (1), (wherein, the carbon atom marked with an * is in the R-configuration, R1 represents a hydrogen atom, a halogen atom, an amino group, a hydroxyl group, a hydroxyamino group, a nitro group, a cyano group, a sulf ...


6
Yasumichi Fukuda, Yoshikazu Asahina, Ayako Nakamura, Kenji Fujita, Tomohiro Ide, Fumiyoshi Kobayashi, Shinji Kobayashi, Kanji Komatsu, Masanori Yamamoto: Glucokinase activator. Kyorin Pharmaceutical, Teijin Pharma, Wenderoth Lind & Ponack L, May 8, 2012: US08173649

A compound represented by the following formula (1): (wherein the carbon atom denoted by * is in the R-configuration; R1 and R2 are each independently a hydrogen atom, a halogen atom, an amino group, a hydroxyl group, a hydroxyamino group, a nitro group, a cyano group, a sulfamoyl group, a C1-C6 alk ...


7
Tomohiro Ide, Naoki Kobayashi, Yunike Akasaka, Takashi Komine, Koji Murakami: AMPK activator screening method, and AMPK activator. KYORIN PHARMACEUTICAL, Wenderoth Lind & Ponack L, January 9, 2018: US09863955

A method for screening an AMPK activator, wherein inhibition of an interaction between prohibitin and AMPK is used as an index is provided. Besides, an AMPK activator comprising, as an active ingredient, a compound inhibiting an interaction between prohibitin and AMPK, and a prohibitin-AMPK complex ...


8
Yasumichi Fukuda, Yoshikazu Asahina, Kazuya Yokota, Koji Murakami, Tomohiro Ide: Bicyclo derivative. Wenderoth Lind & Ponack, July 19, 2007: US20070167501-A1

A novel bicyclo derivative represented by the following general formula (1), or a pharmaceutically acceptable salt thereof, acts as an effective DPP-IV inhibitor: One example is (2S,4S)-1-[[N-(4-methylbicyclo[2.2.2]oct-1-yl)amino]acetyl]-4-fluoropyrrolidine-2-carbonitrile).


9
Yasumichi Fukuda, Yoshikazu Asahina, Satoru Katayama, Taku Shibue, Koji Murakami, Tomohiro Ide: Bicycloamide Derivative. Kyorin Pharmaceutical, Wenderoth Lind & Ponack, November 15, 2007: US20070265320-A1

Novel bicycloamide derivatives (general formula (1)) and pharmaceutically acceptable salts thereof effectively inhibit DPP-IV. The bicycloamide derivatives are represented by the general formula (1): Pharmaceutically acceptable salts thereof are also included (Example: (2S,4S)-1-[[(4-carbamoylbicycl ...


10
Yasumichi Fukuda, Yoshikazu Asahina, Ayako Nakamura, Kenji Fujita, Tomohiro Ide, Fumiyoshi Kobayashi, Shinji Kobayashi, Kanji Komatsu, Masanori Yamamoto: Glucokinase activator. Wenderoth Lind & Ponack, January 21, 2010: US20100016304-A1

A compound represented by the following formula (1): (wherein the carbon atom denoted by * is in the R-configuration; R1 and R2 are each independently a hydrogen atom, a halogen atom, an amino group, a hydroxyl group, a hydroxyamino group, a nitro group, a cyano group, a sulfamoyl group, a C1-C6 alk ...